Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Eriksson

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
The International Journal of Neuropsychopharmacology|August 21, 2009
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled studyBorwin Bandelow, Guy Chouinard, Julio Bobes, et al.
Clinical Drug Investigation|April 25, 2014
Clinical pharmacokinetics of the nicotinic channel modulator dexmecamylamine (TC-5214) in subjects with various degrees of renal impairmentSofie Alverlind, Stéphane Barassin, Per Dalén, et al.
Psychiatry Research|May 11, 2021
Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSDAnne Krogh Nøhr, Hans Eriksson, Mary Hobart, et al.
Neuropsychiatric Disease and Treatment|January 19, 2018
Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studiesEmmanuelle Weiller, Catherine Weiss, Christopher P Watling, et al.
Journal of Comparative Effectiveness Research|August 30, 2014
Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar maniaMachaon Bonafede, Julie C Locklear, Peter Wahlqvist, et al.
International Clinical Psychopharmacology|October 1, 2010
Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trialMartin A Katzman, Olga Brawman-Mintzer, Efren B Reyes, et al.
Journal of Affective Disorders|March 19, 2013
Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorderEduard Vieta, Michael Bauer, Stuart Montgomery, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|February 11, 2014
Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baselineBorwin Bandelow, Michael Bauer, Eduard Vieta, et al.
The Journal of Clinical Psychiatry|July 8, 2011
A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorderWilliam G Honer, G William MacEwan, Alain Gendron, et al.
International Journal of Bipolar Disorders|December 16, 2014
Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled studyMichel S Bourin, Emanuel Severus, Juan P Schronen, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
The International Journal of Neuropsychopharmacology|August 21, 2009
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled studyBorwin Bandelow, Guy Chouinard, Julio Bobes, et al.
Clinical Drug Investigation|April 25, 2014
Clinical pharmacokinetics of the nicotinic channel modulator dexmecamylamine (TC-5214) in subjects with various degrees of renal impairmentSofie Alverlind, Stéphane Barassin, Per Dalén, et al.
Psychiatry Research|May 11, 2021
Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSDAnne Krogh Nøhr, Hans Eriksson, Mary Hobart, et al.
Neuropsychiatric Disease and Treatment|January 19, 2018
Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studiesEmmanuelle Weiller, Catherine Weiss, Christopher P Watling, et al.
Journal of Comparative Effectiveness Research|August 30, 2014
Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar maniaMachaon Bonafede, Julie C Locklear, Peter Wahlqvist, et al.
International Clinical Psychopharmacology|October 1, 2010
Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trialMartin A Katzman, Olga Brawman-Mintzer, Efren B Reyes, et al.
Journal of Affective Disorders|March 19, 2013
Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorderEduard Vieta, Michael Bauer, Stuart Montgomery, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|February 11, 2014
Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baselineBorwin Bandelow, Michael Bauer, Eduard Vieta, et al.
The Journal of Clinical Psychiatry|July 8, 2011
A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorderWilliam G Honer, G William MacEwan, Alain Gendron, et al.
International Journal of Bipolar Disorders|December 16, 2014
Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled studyMichel S Bourin, Emanuel Severus, Juan P Schronen, et al.
Pageof 6